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Protein kinases are attractive therapeutic targets for various indications  
including cancer, cardiovascular, neurodegenerative and autoimmune diseases. This 
is due to the fact that they play key roles in the regulation of cell cycle, metabolism, 
cell adhesion, angiogenesis, regeneration and degeneration. Protein kinase fami-
lies share a common catalytic core and hence usually display clear sequence and 
structural similarity. These sequence and structural similarities can lead to a lack of 
selectivity and off-target toxicity of drug candidates. The lack of selectivity can be 
beneficial but can also cause adverse toxicities which result in the discontinuation of 
promising drug candidates. The chapter reviews the challenges and common toxici-
ties of protein kinase inhibitors and the latest advances in in-vitro and in-silico 
assays to screen for selectivity. The various methods for quantifying selectivity of 
kinase inhibitors and future directions including emerging more selective and safer 
kinase inhibitors have also been discussed.
Keywords: Selectivity, Kinase inhibitors, Toxicity
1. Introduction
Protein kinases belong to a huge family of more than 500 enzymes that 
phosphorylate proteins in response to an external stimulus, via transfer of the 
γ-phosphate group from ATP to serine, threonine, or tyrosine residues on the target 
protein [1]. By doing so they regulate the function of many proteins, and mediate 
and influence a variety of cellular processes including proliferation, metabolism, 
adhesion, angiogenesis, regeneration and degeneration [2]. Since most protein 
kinases are involved in pivotal biological reactions, it is not surprising that dysregu-
lation of the activities of kinases is the hallmark of many pathological conditions 
such as cancer [3], autoimmunity [4], inflammation [5], and neurological disorders 
[6]. In particular, genetic alteration in various protein kinases is associated with 
their over-expression and disease pathology, but also with drug response and 
resistance. Accordingly, more than 250 kinase inhibitors (KIs) are currently under-
going clinical trials and more than 50 have been approved for use by the Food and 
Drug Administration (FDA) [7]. Even though most therapeutic agents are mainly 
for oncologic indications such as imatinib (first small molecule KI approved for 
chemotherapy in 2001), gefitinib, sorafinib, erlotinib, dasatinib and crizotinib, 
there are also emerging KIs for other indications such as rheumatoid arthritis (RA), 
inflammatory bowel disease, alopecia areata, psoriasis, idiopathic pulmonary fibro-
sis, organ rejection prophylaxis, glaucoma and neurodegenerative diseases such as 
Alzheimer disease [8]. In fact, KIs have become one of the most prevalent druggable 
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targets with an estimated one-third of drug discovery programs aimed at develop-
ing KIs. Kinase inhibitors have transformed the treatment of many cancers and are 
showing the same promise for other indications. However, their development has 
been challenging due to severe toxicities observed in preclinical studies and clinical 
trials [9, 10].
Most of the approved KIs are small molecules, which may be classified into six 
main groups according to their binding site on the enzyme [11, 12]: KIs which bind 
to the ATP pocket in the active conformation of a kinase are classified as Type I; 
KIs that bind adjacent to the ATP pocket (adenine binding residues) of the unphos-
phorylated inactive conformation of kinases are classified as Type II; non-ATP 
competitive inhibitors that bind within the cleft between the small and large lobes 
close to the ATP binding pocket are classified as Type III; allosteric inhibitors that 
bind away from the ATP cleft are classified as Type IV; agents that span two distinct 
regions of the protein kinase domain are classified type V inhibitors; and agents that 
form covalent bonds with their target enzyme are classified type VI inhibitors [7].
These different binding modes not only influence the potency and mechanism of 
action of these inhibitors, but may also affect their selectivity and consequently their 
safety profile. Since type I inhibitors bind to the well-conserved ATP binding site 
shared by most protein kinases, these inhibitors are often less selective, and interact 
with multiple members of the protein kinase family. For example, most of the ATP-
competitive inhibitors such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib 
that successfully target the oncoprotein kinase ABL1, exhibit notable off-target 
activities on kinases such as c-KIT, CSF1R, and PDGFRA/B [8] Figure 1 shows an 
Figure 1. 
Crystal structures of representative kinases complexed with small molecule inhibitors at the conserved ATP 
active site. A) Human Abl kinase domain in complex with imatinib. PDB ID: 2HYY. B) DDR1 bound to 
VX-680. PDB ID: 6BRJ. C) Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib, 
PDB ID: 4XUF. D) The ROR1 Pseudokinase Domain Bound To Ponatinib. PDB ID: 6TU9. E) FGFR4 
in complex with Ponatinib. PDB: 4UXQ. F) overlay of the five crystal structures (A-E) showing the high 
structural homology between the different kinases. The small molecule inhibitors are shown in green sticks. 
Images were drawn using the maestro software [13].
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overlay of the crystal structures of five representative kinases from different families 
with their respective small molecule inhibitors bound to the ATP active site, dem-
onstrating why type I inhibitors usually have low selectivity. This cross reactivity is 
associated with toxicities in the clinic and often leads to discontinuation of promising 
drug candidates during development as will be described in this chapter. Type II KIs 
demonstrate improved selectivity profiles compared with type I inhibitors because 
they bind adjacent to the ATP binding pocket in the inactive kinase conformational 
state, a site which is less conserved within the kinome [14]. Type III-VI inhibitors, 
which are non-ATP competitive inhibitors that often do not bind to conserved 
residues, offer greater selectivity and reduced toxicity compared to other types of 
KIs as they are likely to have less off-target effects [15–17]. In addition, the toxicity 
profiles of KIs depend on which kinase was targeted, the affinity of the inhibitor for 
the particular kinase and on the role that this kinase plays in intracellular signaling 
and overall cell function.
Off-target activity of KIs are not necessarily limited to kinases. Non-kinase 
off-targets of KIs often remain undiscovered, and may lead to misinterpretation of 
the cause of toxicity [18]. That is, KIs may also bind to other enzymes, ion chan-
nels and/or receptors and thus performing a full binding profile is important to 
understand all potential targets as well as subsequently assessing off-target activity. 
However, off-target activity is not always a cause for concern for therapeutic agents 
as the off-target activity may have positive therapeutic outcomes. Multi-targeted 
KIs may target a pathway at different points e.g. upstream and downstream and 
thus multi-targeted KIs may have improved efficacy compared to more selective 
inhibitors. Additionally, KIs with off-target activity in different pathways may be 
beneficial for targeting different indications [19, 20].
In addition to small molecule inhibitors, there are also several monoclonal 
antibodies (mAbs) that specifically and selectively target and block the extracel-
lular domain of receptor tyrosine kinases such as epidermal growth factor receptor 
(EGFR, HER1, ErbB-1), and human epidermal growth factor receptor 2 (HER2, 
ErbB-2) [21]. By targeting the extracellular part of the receptor tyrosine kinase, the 
mAb is able to block the binding of the natural ligand, avoid receptor conforma-
tional rearrangement essential to the activation of the kinase and thus the activa-
tion of the downstream signaling pathways. Even though mAbs therapies are often 
considered as very specific and safer therapeutic agents, anti-EGFR antibodies, 
such as cetuximab and panitumumab, have been associated with severe skin, renal, 
and gastrointestinal toxicities as they block essential cellular signaling pathways 
[22, 23]. In addition, the development of chemoresistance in a large portion of 
patients due to the ability of cells to re-activate pro-angiogenic factors via alternate 
pathways (i.e. increasing VEGF production), also hampered the success of these 
drugs in the clinic [24].
This chapter will review the challenges of developing safe protein KIs, the latest 
advances in assays to screen for selectivity and future directions.
2. Common toxicities with kinase inhibitors
Adverse effects from KIs may be classified into on- and off-target toxicities. 
“On-target” toxicity results when the inhibition of the targeted kinase is responsible 
for both the intended pharmacodynamic effect and the unintended toxicity. On 
the contrary, “off-target” toxicity is the result of low selectivity and inhibition of 
kinases for which the drug was not intended.
KIs are associated with undesirable adverse reactions that impact on quality of 
life and compliance of patients, even though less than traditional chemotherapy. 
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These effects include cardiovascular toxicity, hepatotoxicity, hematotoxicity, 
dermatological and ocular toxicities, gastro-intestinal symptoms, hyperphospha-
temia and tissue mineralization [25]. For example, EGFR-Tyrosine KIs (TKIs) are 
typically associated skin rash, diarrhea, hepatotoxicity, stomatitis, interstitial lung 
disease and ocular toxicity, but these effects are usually mild in most cases [26]. 
In this chapter we decided to focus on the mechanism of three major toxicities: 
cardiovascular toxicity, hepatotoxicity and hematotoxicity. This decision was not 
based on the incidence of the side effects but rather the impact of these particular 
side effects on patients. These side effects have a great impact on patients due to 
the effects on their well-being and compliance to treatment. In addition, these 
particular side effects are a major cause for discontinuing the development of many 
molecules. Therefore, improving the selectivity of compounds in a manner that will 
not interfere with or avoid the mechanisms outlined below is important.
2.1 Cardiovascular toxicity
Many protein kinases are critical for normal function of cardiomyocytes  
and/or the vasculature, and thus their inhibition results in “on-target” cardiotox-
icity due to the overlap in the targeted pathway for cancer progression and the 
pathway for regulation of cardiac function [27]. Protein kinase signaling plays a 
significant role in cardiac hypertrophy (increase in cell size) under physiological 
conditions in response to an increased workload, such as exercise or pregnancy, 
but the relative importance of individual kinases is not clear. Microarray analysis 
of protein kinase mRNA expression in dozens of non-failing human heart biopsies 
detected 402 protein kinase mRNAs that are constantly expressed under normal, 
non-pathologic conditions [28]. Therefore, it is not surprising that many KIs have 
a cardiovascular (CV) toxicity warning and precautions in their US prescribing 
information. The adverse cardiac events listed in the US prescribing information 
for cancer patients following treatment with KIs include: QT prolongation, hyper-
tension, left ventricular dysfunction (LVD), congestive heart failure (CHF), acute 
coronary syndromes (ACS), and myocardial infarction (MI) [27]. For example, 
targeting VEGF is associated with hypertension, and targeting human epidermal 
growth factor receptor 2 (HER2), VEGFR, and/or Bcr-Abl is often accompanied 
with LVD and CHF [29, 30]. The consequence cardiac toxicity among new KIs due 
to “on-target” activities and lack of selectivity, limits development of new drugs 
even when targeting life-threatening therapeutic indications such as cancer.
Not all KIs, however, are prone to cardiotoxicity. More selective KIs targeting 
the Janus kinase (JAK) family, such as tofacitinib targeting Janus kinase (JAK) 1/3 
for the treatment of RA, psoriatic arthritis, ulcerative colitis, and the selective JAK2 
inhibitor, fedratinib, are not associated with cardiotoxicity (see Table 1). Similarly, 
inhibitors of mammalian target of rapamycin (mTOR) such as sirolimus, temsiroli-
mus and everolimus developed for different malignancies are also not accompanied 
with cardiotoxicity (see Table 1, US prescribing information for sirolimus, temsi-
rolimus and everolimus) despite the role of mTOR signaling in cardiac physiology 
[31]. These examples demonstrate that cardiotoxicity may be overcome by increas-
ing selectivity.
2.2 Hepatotoxicity
Hepatotoxicity has been reported for several TKIs and it is estimated to affect 
approximately 5% of patients [32]. The clinical effects have ranged from mild 
elevation in transaminases to progressive irreversible cirrhosis, which has resulted 




























Indication Most common adverse reactions and warnings (as mentions in the US 
prescribing information)
BCR-Abl inhibitors
Bosutinib 2012 BCR-Abl Chronic myelogenous leukemias Diarrhea, nausea, thrombocytopenia, rash, increased alanine 
aminotransferase, abdominal pain, increased aspartate aminotransferase, 
thrombocytopenia, vomiting, anemia, fatigue, pyrexia, cough,
headache, alanine aminotransferase, and edema
Dasatinib 2006 BCR-Abl, 
SRC 
kinase
Chronic myelogenous leukemias Myelosuppression (thrombocytopenia, neutropenia, and anemia may 
occur), fluid retention events, diarrhea, headache, skin rash, hemorrhage, 
dyspnea, fatigue, nausea, and musculoskeletal pain
Imatinib 2001 BCR-Abl Philadelphia chromosome-positive CML or ALL, aggressive 
systemic mastocytosis, chronic eosinophilic leukemias, 
dermatofibrosarcoma protuberans, hypereosinophilic 
syndrome, gastrointestinal stromal tumors, myelodysplastic/
myeloproliferative disease
Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, 
hepatotoxicity, heart failure and left ventricular dysfunction, edema, nausea, 
vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and 
abdominal pain
EGFR and VEGFR inhibitors
Cetuximab 2004 EGFR Head and neck cancer and colorectal cancer Fatal infusion reactions and Cardiopulmonary arrest. Cutaneous adverse 
reactions (including rash, pruritus, and nail changes), headache, diarrhea, 
and infection
Panitumumab 2006 EGFR Colorectal Cancer Skin toxicities (i.e., erythema, dermatitis acneiform, pruritus, exfoliation, 
rash, and fissures), paronychia,
hypomagnesemia, fatigue, abdominal pain, nausea, diarrhea, and 
constipation
Erlotinib 2004 EGFR NSCLC, pancreatic cancers NSCLC: rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection 
and vomiting.
Pancreatic cancer: fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, 
vomiting, weight decrease, infection, edema, pyrexia, constipation, bone 
pain, dyspnea, stomatitis and myalgia.






















Indication Most common adverse reactions and warnings (as mentions in the US 
prescribing information)
Lapatinib 2007 HER2 and 
EGFR
HER2-positive breast cancers Hepatotoxicity, diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, 
vomiting, and fatigue. May prolong the QT interval in some patients or 
decreases in left ventricular ejection fraction,
Pazopanib 2009 VEGFR Advanced renal cell carcinoma, advanced soft tissue sarcoma Hepatotoxicity
Advanced renal cell carcinoma: diarrhea, hypertension, hair color changes 
(depigmentation), nausea, anorexia, and vomiting.
Advanced soft tissue sarcoma: fatigue, diarrhea, nausea, decreased weight, 
hypertension, decreased appetite, vomiting, tumor pain, hair color 
changes, musculoskeletal pain, headache, dysgeusia, dyspnea and skin 
hypopigmentation.
Prolonged QT, Arterial thrombosis, cardiac dysfunction and hemorrhagic 
events were reported.
Sorafinib 2005 VEGFR Hepatocellular carcinomas, renal cell carcinomas, thyroid 
cancers (differentiated)
Diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight 
loss, decreased appetite, nausea, gastrointestinal and abdominal pains, 
hypertension, and hemorrhage.
Sunitinib 2006 VEGFR Gastrointestinal stromal tumors, pancreatic neuroendocrine 
tumors, renal cell carcinomas
Hepatotoxicity, fatigue, asthenia, fever, diarrhea, nausea, mucositis/
stomatitis, vomiting, dyspepsia, abdominal pain, constipation, hypertension, 
peripheral edema, rash, hand-foot syndrome, skin discoloration, dry skin, 
hair color changes, altered taste, headache, back pain, arthralgia, extremity 








RA Series infections, malignancy and thrombosis, upper respiratory tract 
infections, nausea, herpes simplex, and herpes zoster
Ruxolitinib 2011 JAK1/
JAK2
Myelofibrosis Thrombocytopenia, anemia, neutropenia bruising, dizziness and headache




























Indication Most common adverse reactions and warnings (as mentions in the US 
prescribing information)
mTOR inhibitors
Sirolimus 1999 mTOR Kidney transplant, lymphangioleiomyomatosis Kidney transplant: peripheral edema, hypertriglyceridemia, hypertension, 
hypercholesterolemia, creatinine increased, abdominal pain, diarrhea, 
headache, fever, urinary tract infection, anemia, nausea, arthralgia, pain, and 
thrombocytopenia
Lymphangioleiomyomatosis: stomatitis, diarrhea, abdominal pain, nausea, 
nasopharyngitis, acne, chest pain, peripheral edema, upper respiratory tract 
infection, headache, dizziness, myalgia, and hypercholesterolemia
Temsirolimus 2007 mTOR Advanced renal cell carcinomas Rash, asthenia, mucositis, nausea, edema, and anorexia, anemia, 
hyperglycemia, hyperlipemia, hypertriglyceridemia, elevated alkaline 
phosphatase, elevated serum creatinine, lymphopenia, hypophosphatemia, 
thrombocytopenia, elevated AST, and leukopenia.
Everolimus 2009 mTOR HER2-negative breast cancers, pancreatic neuroendocrine 
tumors, renal cell carcinomas
Advanced RCC: stomatitis, infections, asthenia, fatigue, cough, and diarrhea.
SEGA: stomatitis, upper respiratory tract infection, sinusitis, otitis media, 
and pyrexia.
CDK inhibitors
Abemaciclib 2017 CDK4/6 breast cancer Diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, 
anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and 
thrombocytopenia
Palbociclib 2015 CDK4/6 Estrogen receptor- and HER2-positive breast cancers Neutropenia, infections, leukopenia, fatigue, nausea, stomatitis, anemia, 
alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased appetite, 
asthenia, and pyrexia
Ribociclib 2017 CDK4/6 Combination therapy for breast cancers Neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, 
constipation, headache and back pain
Table 1. 
List of currently approved KIs, their primary targets, identified off-targets, indication and most common adverse reactions in humans as defined in the drug labels.
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individual patients [33, 34]. As most of TKIs are metabolized by hepatic cytochrome 
P450 enzyme system, clinicians should be aware of potential hepatotoxicity with 
TKIs in patients with liver dysfunction. However, the mechanism for liver toxic-
ity with KIs is not fully clear. Paech et al. [35] studied several approved oncologic 
KIs (erlotinib, imatinib, lapatinib, and sunitinib) associated with liver toxicity in 
human hepatocyte cell lines and in isolated mouse liver mitochondria focusing on 
ATP metabolism. The authors proposed that imatinib (Bcr-Abl TKI) and sunitinib 
(multiple receptor TKI) induce mitochondrial dysfunction and by inhibiting 
complex I and/or III of the electron transport chain of the mitochondria required 
for its function and glycolysis. Lapatinib (HER2 and EGFR TKI) affected mito-
chondria only weakly but inhibited glycolysis, and erlotinib (EGFR TKI) showed 
a slight cytotoxicity in both cell models investigated, although it did not affect the 
mitochondria ATP content in all cell types and did not impair oxidative metabolism. 
Similar mechanism of inhibition of mitochondrial complex I leading to impaired 
mitochondrial and myocyte proliferation was published for imatinib and dasatinib 
(Bcr-Abl and Src TKI) by Bouitbir et al. using C2C12 murine myoblasts and myo-
tubes as well as human rhabdomyosarcoma (RD) cells [36].
In contrast to liver toxicity, it appeared in recent years that TKIs may also pre-
vent or reverse hepatic disease. Accumulating evidence suggests that hepatic stellate 
cells (HSC) play a pivotal role in hepatic fibrogenesis [37], and that phosphoryla-
tion of transcription factors by kinases such as RSK [38] or focal adhesion kinase 
(FAK) [39] promotes stellate cell activation and survival. Therefore, inhibition of 
these kinases either as on-targets or off-targets may reduce hepatic disease.
2.3 Hematotoxicity
Hematotoxicity of KIs includes adverse effects on blood-forming organs such 
as bone marrow or on the constituents of blood, including platelets, leukocytes 
(white blood cells) and erythrocytes (red blood cells). One particular hematotoxic-
ity caused by KIs is myelosuppression, also known as bone marrow suppression. 
Myelosuppression is a decrease in bone marrow activity that results in reduced pro-
duction of blood cells manifested as anemia (decrease in erythrocytes), neutropenia 
(decrease in leukocytes), or thrombocytopenia (decrease in platelets). VEGF and 
its receptors are essential for production of mature blood cells [40, 41], as well as 
are principal regulators of blood vessel formation (angiogenesis) [42]. Accordingly, 
hematologic toxicities have been observed in clinical studies with several multi-
kinase inhibitors such as VEGFRs KIs (i.e. pazopanib, sorafenib, and sunitinib) 
[43], although the frequency and severity varies among the different multi-kinase 
inhibitors, depending on their selectivity and affinity to other kinases [44].
Inhibitors of another two kinases which play roles in hematopoietic activities, 
FLT3 and mTOR, are also associated with hematotoxicities. A broad range of 
hematopoietic activities are mediated through interactions of c-Kit ligand (KL) and 
FLT3 ligand with their receptors: stem cell factor (SCF) and receptor-type tyrosine-
protein kinase FLT3, respectively [45]. The signaling through SCF and FLT3 is 
essential for optimal production of mature haematopoietic cells from stem cells 
[44]. FLT3 is more critical for the generation of lymphoid progenitors, whereas SCF 
regulates erythroid and myeloid platelet-derived growth factor (PDGF) progenitor 
cells. mTOR inhibitors, such as temsirolimus and everolimus, are also associated 
with a significant increased risk of developing anemia and thrombocytopenia 
[46], although they have great therapeutic potential in hematologic diseases such 
as leukemia, lymphoma, myeloma [47]. One possible explanation is that the effect 
of mTOR inhibition on erythropoiesis could be the antigrowth effect of these KIs 
on erythrocytes consequently leading to a lower production and decreased size 
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when compared to normal growth [48]. Thus, low selectivity of various KIs towards 
the above kinases might explain the accompanying hematotoxicity (i.e. imatinib 
inhibits FLT3 as an off-target).
3. Management of kinase inhibitors associated toxicities
The overall risk for development of the discussed toxicities is different between 
inhibitors, indications, patients, and patient medical history, and usually the 
benefit to the patient exceeds the risk associated with development of these adverse 
events. That is, cardiotoxicity can be managed by routine monitoring via methods 
such as electroencephalogram, cardiac biomarkers, and blood pressure during 
the course of treatment, in addition to a comprehensive collection of past medical 
history and risk factors to identify those at increased risk. When there is a risk 
for hepatotoxicity, monitoring and management of serum liver chemistry such 
as elevations of Alanine transaminase (ALT), total bilirubin (TBL) and Alkaline 
phosphatase (ALP) may identify liver injury during treatment and may suggest 
reduction in dosage or replacement of KI. Likewise, anemia may be monitored by 
hematology testing and treatment of iron supplements or erythropoiesis stimulat-
ing agents. Regardless, avoiding these side effects via the development of more 
selective KIs is more advantageous for improving the quality of life of the patients 
and economy rather than management of the side effects post-marketing. The 
complex nature of kinase signaling and the challenges of developing selective KIs, 
suggest that early prediction of selectivity for new molecules and their potential 
for adverse events in the clinic at preclinical stages may assist and improve the 
development of future, safer KIs. Proper use of the tool box of preclinical assays as 
described below may accelerate this goal by identifying and comparing the selec-
tivity of new KIs.
4. Development of selective Protein Kinase Inhibitors
4.1 Methodologies and assays to profile protein kinase inhibitors
Due to the evolving knowledge of the importance of kinases in cell biology 
and function and their problems of selectivity, multiple methodologies have been 
developed to profile KIs. Both radiometric and non-radiometric approaches are 
utilized today. Non-radiometric assays can assess ligand-kinase binding or kinase 
enzymatic activity. However, the radiometric approach assessing kinase enzy-
matic activity is still considered the “gold standard”. Given the increasing demand 
for kinase profiling assays and evolution of technology, several companies have 
developed fee-for-service assays and assay kits [49]. The different methodologies 
and assays are discussed in the sections below and listed in Table 2.
Identifying, quantifying and optimizing the selectivity of compounds became 
critical for both drug development and development of tool compounds for basic 
research [19]. Building our knowledge on the selectivity of compounds and creat-
ing databases aid in the development of structure-selectivity relationships that will 
improve rationale design of selective KIs, progress drug discovery and promote 
inhibitor optimization [65].
Selectivity of KIs is well acknowledged as a challenge in the development of 
safe drugs and tool compounds. ‘Uni-specificity’ refers to compounds that inhibit 
a single kinase more potently than any other kinases. Very few protein KIs dem-
onstrate ‘uni-specificity’, emphasizing the unresolved issue of selectivity amongst 
Protein Kinases - Promising Targets for Anticancer Drug Research
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protein KIs [20]. Investigating and comparing the selectivity of KIs early in their 
development is pivotal to developing more selective and consequently safer KIs. 
Multiple approaches were used to investigate the selectivity of KIs. One approach 
was to concentrate on the ability of a single KI to inhibit kinases within a specific 
subfamily due to the similarity in the ATP binding domain. However, importantly, 
inhibitor type does not guarantee selectivity. Additionally, Anastassiadis et al. [20] 
demonstrated that a substantial percentage of kinase off-target activity occurred 
outside the subfamily of interest. For example, 24% of off-target effects of TKIs 
occurred in the serine/threonine kinase subfamily [20]. Another approach was to 
focus on the ability of a single KI to inhibit kinases within particular pathways due 
to shared functionality. A third and most comprehensive approach is to profile KIs 
against a variety of kinases across the kinome both within and between subfamilies. 
As technology and assay methodology developed, use of broad screening panels 
became more common and revealed that compounds historically believed to be 
selective were in fact not. Today, the best-practice and recommended approach is to 
screen KIs in different kinase assay formats against multiple related and unrelated 
kinases. The broad screening panels should be quantitative and systematic with 
objective criteria to compare between studies. It is important that the assays used 
are optimized, robust, reliable and standardized for multiple, varied kinases. It is 
also preferable for practical use of the assays that they are suitable for high-through-
put designs and economical [19, 20].
4.2 Enzymatic Activity Assays
4.2.1 Radiometric methods
4.2.1.1 Filtration binding assay
The use of [32P]-or [33P]-ATP in a kinase reaction allows phosphorylation of a 
substrate peptide or protein to be measured directly. The filtration binding assay 
approach is the most preferable and the benchmark against which other method-
ologies are compared. Following a kinase reaction utilizing the radiolabeled ATP 
molecules, the labelled substrates are bound to capture membranes such as P81 ion 
exchange filter paper and unchanged ATP/unbound phosphate is washed away. One 
such assay termed HotSpot™ was developed by Reaction Biology Corporation and 
Anastassiadis et al. [20] utilized Reaction Biology Corporation’s HotSpot™ assay 
to demonstrate the selectivity of 178 KIs against 300 recombinant protein kinases. 
Promega’s SignaTECT assay operates on a similar principle, however, the SignaTECT 
assay utilitizes biotinylated substrates and a biotin capture membrane to capture the 
biotinylated substrates with the radiolabeled phosphate for detection [51].
4.2.1.2 Scintillation proximity assay
In order to overcome the necessity for separation and washing steps of the filtra-
tion binding assay, the “mix and read” scintillation proximity assays were developed 
[49]. Reaction Biology Corporation’s 33PanQinase™ is an example of a scintillation 
proximity assay whereby the reaction with [33P]-ATP is performed using microtiter 
plates coated with scintillant for detection [50]. A variety of radio isotypes can be 
utilized in a scintillation proximity assay [49].
Despite the advantages of radiometric methodologies such as universality across 
kinases and low error signal (low false-positive and false-negative rates), the major 
disadvantage of the radiometric methodology is the specialized waste disposal 
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and safety precautions required for working with radioactive material. As a conse-
quence, non-radioactive methodologies were developed.
4.2.2 Fluorescent based methods
4.2.2.1 Fluorescence Intensity assay
A number of fluorescence intensity assays are available whereby the readout is 
simply fluorescent intensity (FI). DiscoverX ADP Hunter™ and ADP Quest™FI 
assays use linked reactions that use ADP, pyruvate kinase, pyruvate oxidase and 
horseradish peroxidase to convert a fluorescent dye precursor (ADHP (10-Acetyl-
3,7-dihydroxyphenoxazine) to fluorescent resorufin, the source of the fluorescent 
intensity signal [52]. Bellbrook Labs Transcreener® ADP FI Assay measures ADP 
levels. This is accomplished by utilizing an IRDye® QC-1 quencher conjugated to 
an anti-ADP antibody to quench the signal from an ADP Alexa Fluor® 594 tracer. 
Once ADP is produced, ADP displaces the fluorescent tracer allowing detection of 
the fluorescent signal from the fluorescent tracer [53].
4.2.2.2 Fluorescent polarization assays
Exciting molecules with polarized light promotes rotational movement. The 
speed of the rotational movement depends on the molecular weight of the com-
pound. That is, high molecular weight molecules rotate slower than low molecular 
weight molecules. Molecular Device developed a “mix and read” FP assay whereby 
following kinase reaction a fluorescently labelled, phosphorylated substrate binds 
to a large nanoparticle increasing the molecular weight, decreasing rotational speed 
and increasing the polarization of the phosphorylated peptide or protein [54]. 
However, false-positive and false-negatives have been reported utilizing the FP 
methodology [49].
4.2.2.3 Fluorescent resonance energy transfer (FRET)
Fluorescent resonance energy transfer (FRET) relies on the transfer of energy 
between donor and acceptor molecules that occurs when the two molecules 
come into close proximity and following excitation of the donor molecule. Many 
companies have utilized this technology to develop assays for kinase profiling 
including Invitrogen’s Z’-LYTE Kinase Assay utilized in their SelectScreen Kinase 
Profiling Service. In invitrogen’s Z’-LYTE Kinase Assay, two fluorescent proteins 
that make up FRET donor and acceptor molecules are added to substrates, then 
following the kinase reaction, the non-phosphorylated substrates are cleaved by a 
protease interrupting the energy transfer between the donor and acceptor fluoro-
phores. Therefore, the emission wavelength differs depending on if the substrate 
was phosphorylated or not. The assay relies on identification of the amino acid 
sequence of the relevant substrate and has been validated for more than 200 
kinases [49, 66].
4.2.2.4 Time-resolved fluorescence (TRF)
Time-resolved fluorescence (TRF) involves the use of fluorophores that decay 
over a longer period of time than traditionally used fluorophores and the decay 
following light excitation of these fluorophores can be monitored as a function 
of time. Lanthanide chelates such as Europium, Samarium and Terbium are 
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examples of such non-traditional fluorophores with long decay times. PerkinElmer’s 
DELFIA® assay is available as a TRF assay that utilizes lanthanide chelate tagged 
antibodies to detect phosphorylated substrates [49, 56].
4.2.2.5 Time-resolved fluorescence resonance energy transfer (TR-FRET)
A time-resolved fluorescence resonance energy transfer (TR-FRET) assay 
combines the principle of FRET with donor and acceptor molecules with TRF 
whereby one of the molecules is a fluorophore with an extended decay time [49]. 
For example, in addition to Invitrogen’s Z’-LYTE FRET assay, Invitrogen also offer 
several TR-FRET assays (LanthaScreen Activity assay, LanthaScreen Eu Kinase 
binding assay [discussed below in Section 1.3.2] and Adapta Assay). The Adapta 
Assay utilizes a Europium-labeled anti-ADP antibody and an Alexa Fluor® 647 
labeled ADP tracer to examine ADP levels following a kinase reaction. Without 
the presence of ADP, the anti-ADP antibody and ADP tracer bind to create the 
TR-FRET signal. ADP disrupts the binding of the antibody and tracer reducing 
the signal. Alternatively, the LanthaScreen® activity assay involves a fluorophore-
labelled substrate that when phosphorylated is bound by Terbium-labeled antibody 
to generate the FRET signal [57, 58]. Similarly, PerkinElmer’s Lance® Ultra kinase 
assay utilizes ULight™-labeled substrate that when phosphorylated is bound by 
Europium-labeled antibody to generate the FRET signal. Similar to the Z’-LYTE 
Kinase Assay, the LanthaScreen Activity assay and Lance® Ultra kinase assay both 
rely on identification of the amino acid sequence of the relevant substrate [59].
4.2.3 Luciferase reporter assay
Cell-based luciferase reporter assays that produce bioluminescence are common 
to monitor the activity of cellular processes. Cell-based luciferase reporter assays 
require luciferin, luciferase enzyme and sometimes ATP. The Firefly luciferase 
enzyme converts luciferin into oxiluciferin in the presence of ATP emitting a light 
photon. As the conversion of luciferin to oxiluciferin relies on ATP, the luciferase 
enzyme can be used to detect the amount of ATP following a kinase reaction and the 
amount of luminescence positively correlates with the amount of ATP [49, 67]. An 
example of a commercially available luciferase assay for kinase profiling is Promega’s 
Kinase-Glo® platform [60].
It is also important to differentiate when utilizing a luciferase reporter assay 
between compounds that legitimately inhibit a kinase from compounds that 
interfere with the assay itself. That is, luciferase itself may be targeted by KIs [67]. 
Dranchak et al. [67] investigated the ability 367 compounds in the GSK published 
protein kinase inhibitor set to inhibit two commonly used types of luciferase 
enzymes (firefly luciferase [FLuc; ATP-dependent] and renilla renififormis lucifer-
ase [RLuc; ATP-independent]). Approximately 6% of the KIs inhibited FLuc activ-
ity whereas approximately 0.5% inhibited RLuc activity. Therefore, the specific 
luciferase utilized and the potential interactions of KIs with the luciferase should 
be taken into consideration when choosing an appropriate assay platform for kinase 
profiling using luciferase [67].
4.2.4 Electrophoretic Mobility Shift Assays
Phosphorylation of a substrate causes an increase in the negative charge of 
the substrate. As a consequence, phosphorylated substrates can be separated and 
detected using electrophoretic technologies. The Caliper Life Sciences’ Nanosyn 
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Assay takes advantage of these properties of phosphorylated substrates (usually 
fluorescently labelled peptides and proteins) and utilizes a microfluidic chip for the 
assay reaction and electrophoretic detection [49, 61, 68]. Elkins et al. [68] utilized 
this assay to examine the selectivity of the GSK published protein kinase inhibitor 
set against 224 recombinant kinases with a 50% inhibition threshold and identi-
fied that there are different kinases targeted by multiple compounds, kinases not 
inhibited by any of the compounds and kinases inhibited by only one compound.
4.3 Ligand-kinase binding assays
Measuring the effect of ligands on the enzymatic activity of kinases has tra-
ditionally been the “go to” approach. However, enzymatic activity assays require 
individual optimization in order to receive an acceptable signal-to-noise ratio as 
well as identification of upstream signaling partners and applicable substrates. The 
requirements for optimization of enzymatic activity assays cannot always be met 
and individual optimization of the assays for each kinase can be costly and time 
consuming. Therefore, binding assays were developed utilizing different technolo-
gies including competitive binding assays and differential scanning fluorimetry to 
facilitate high-throughput kinase profiling [64, 69]. Although suitable to enable 
high-throughput screening, ligand-kinase binding assays do not always predict 
enzymatic activity of a compound with the particular kinase [20, 69].
4.3.1 Competitive binding assays
One option for a competitive binding assay is Invitrogen’s LanthaScreen Eu 
Kinase binding assay using TR-FRET technology as described in Section 4.2.2.5. 
That is, the assay operates whereby a Europium-labeled antibody is targeted 
against a tagged kinase and an Alexa Fluor® 647 labeled substrate are used to gen-
erate the FRET signal. Inhibitor binding to the kinase prevents substrate binding 
and disrupts the FRET signal [63].
An alternative approach is the DiscoverX’s KINOMEscan assay utilizing immo-
bilized ligands [62]. The KINOMEscan platform was originally published by Ambit 
Biosciences. The KINOMEscan platform involves phage or DNA tagged kinases and 
immobilized ligands. The ligands are biotinylated and then bound to streptavidin-
coated magnetic beads attached to solid supports. The immobilized ligands compete 
with compounds for binding to the kinase. ATP-binding and allosteric KIs can 
compete with the immobilized ligands. Kinase that is unbound to the immobilized 
ligand is removed via wash steps. The amount of kinase bound to the immobilized 
ligands is then quantified using qPCR identifying the phage or DNA tag attached 
to the kinase. The assay has been validated for more than 450 kinases (wild-type 
and mutant) [69–71]. Utilizing this technique, Davis et al. [69] screened 72 KIs 
and demonstrated that type II inhibitors are more selective than type I inhibitors 
with the majority of type II inhibitors demonstrating binding to 20% or less of the 
total kinases screened. However, a KI belonging to the type II class does not guar-
antee selectivity with a subset of type II inhibitors binding to 40–50% of kinases 
screened [69].
4.3.2 Differential Scanning Fluorimetry
Upon binding of a ligand to a protein, such as a kinase, the thermal properties of 
the protein stabilize and the melting temperature increases. The unfolded, unbound 
kinase that is not stabilized is detected by a dye that binds to unfolded proteins and 
fluoresces. This methodology is termed differential scanning fluorimetry (DSF). 
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SYPRO orange is a suitable fluorescent dye for this application due to the high signal-
to-noise ratio and comparably high excitation wavelength [64, 72]. Fedorov, Niesen 
and Knapp [64] demonstrated that the data generated using the KINOMEscan 
assay developed by Ambit Biosciences and described above (Section 4.3.1) highly 
correlated with their data generated using DSF with an r2 value of 0.949. A major 
advantage of the thermal stability shift methodology is that knowledge of the amino 
acid sequence of the substrate or kinase is not required and specialized antibodies 
are also not required [64]. Additionally, Anastassiadis, et al. [20] compared the DSF 
method to Reaction Biology Corporation’s radiometric method and found a signifi-
cant correlation between the two methodologies. However, the DSF method did 
demonstrate false-positives and false-negatives and thus emphasizing that binding 
does not necessarily predict enzymatic activity [20].
4.4 Computational analysis
Computational kinase selectivity profiling methods can be used to predict 
the selectivity of KIs and rationally design KIs with desired profiles across a 
large number of kinases and avoid the limitations of activity and binding assays. 
However, computational approaches are dependent on the quality of the available 
structure–activity data or require extensive computational analysis [73]. Improved 
computational approaches take advantage of the conservational nature of the 
kinome and shared binding patterns of KIs as well as profiling data generated for 
multiple kinases across the classes and kinome and kinase 3D structures. Kinase 
inhibition profiling data including both positive and negative (little or no effect) 
data are invaluable to the evaluation of computational approaches for predicting KI 
selectivity [74]. The large volume of data generated to date paved the way for the 
development of machine learning and artificial intelligence approaches that allow 
for prediction of results for KIs and kinases not included in the dataset [19, 73–75]. 
With the accumulation of structure–activity data over the years, the literature has 
been minded to create both commercially and publically available databases with 
data from diverse sources such as ChEMBL, Kinase SARfari and GVK Biosciences 
kinase inhibitor database. The kinase-inhibitor profiling panels already discussed 
here such as those generated by Karaman [70], Anastassiadis [20] and Davis [69] as 
well as other databases such as the 3D structures available in PDB were also used to 
generate numerous computational approaches. The size of the gatekeeper residue, 
hydrogen and covalent bonds, the flexibility of the hinge loop connecting kinase 
domains as well as kinase-inhibitor data were all used to generate computational 
approaches. The KI data can be represented either as binary yes-no or weighted 
by affinity or inhibitory activity and can be used to generate connectivity maps to 
predict either kinases, KIs or diseases [74]. Lo et al. [73] developed a computational 
approach based on searching for structural similarity of the ligand binding sites and 
determining a PocketFEATURE score (PFS). Specifically, a kinase database entitled 
‘KinomeFEATURE’ of approximately 2850 kinase structures was constructed to 
predict selectivity of 15 known KIs with greater than 90% accuracy. Therefore, 
computational approaches are becoming more widely used and useful for the 
purpose of predicting selectivity and rationally design KIs [73].
4.5 Quantification of selectivity
In order to aid in the ability to compare data between studies and assay 
methodologies to identify and compare the selectivity of inhibitors, different 
quantitative measures of selectivity have been developed. These measures involve 
condensing large datasets into single values for each inhibitor. Such measures 
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include the selectivity score, Gini coefficient score and selectivity entropy score 
described below. However, the selectivity score for a particular KI takes into 
consideration all kinases in a dataset and rely upon the size and diversity of the 
kinases in the dataset [76].
4.5.1 Selectivity score
In order to generate a selectivity score for a particular inhibitor, the number 
of kinases bound by this specific inhibitor with Kdor IC50 values that meet pre-
defined threshold criteria should be divided by the total number of distinct kinases 
screened in a specific assay [20, 69, 70]. The predefined threshold can be a specific 
concentration e.g. 3 μM [S(3 μM)] or percentage e.g. 50% [S(50%)]. For example, 
Karaman et al. [70] from Amit Biosciences utilized the KINOMEscan to screen 38 
KIs against 317 kinases and calculated selectivity scores S(3 μM) and S(100 nM) 
whereby Kd < 3 μM and Kd < 100 nM, respectively. Via the use of the selectivity 
score, Karaman et al. [70] showed that the compounds screened demonstrated a 
fairly even distribution of selectivity scores from 0.01 to 0.57 (1–57%).However, 
Karaman et al. [70] also demonstrated that the composition of the kinases in the 
screened database significantly affected the outcome. That is, the selectivity score 
varied greatly by adjusting the number of kinases screened and randomly selecting 
kinases preserved the results better than a systematic selection. Karaman et al. [70] 
also described a selectivity score to describe off-target affinities whereby a ratio of 
the Kd for the off-target to the Kd of the primary target is generated and then the 
number of ratios below 10 is then divided by the total number of distinct kinases 
assayed. This selectivity score was also termed S(10x). Later, Davis et al. [69] (Amit 
Biosciences) also used the KINOMEscan to screen 72 KIs against 442 kinases and 
demonstrated that the majority (64%; 46 out of 72) of inhibitors bound to <20% 
of the total distinct kinases screened by them (totaling 386) with a S(3 μM) score 
of <0.2.
The selectivity score is not limited to the assay type or assay technology facilitat-
ing comparisons between compounds, studies and assays [70]. The selectivity score 
is, however, dependent on the threshold set for defining the score such as 3 μM vs. 
100 nM or 50% vs. 70% inhibition [20].
4.5.2 Gini Coefficient
The Gini coefficient has been described as a less arbitrary tool for evaluating 
selectivity compared to the selectivity score described above as the Gini coefficient 
does not rely on defining a threshold value. To calculate the Gini coefficient, the % 
inhibition of a compound at a single concentration is rank ordered, summed and 
normalized to generate a plot of rank order vs. fraction of cumulative effect of each 
target. Then, the deviation from the linear plot is calculated and a greater deviation 
from the linear plot indicates a less specific compound. A Gini score of 1 indicates 
an inhibitor that targets one kinase whereas a score of 0 indicates a compound that 
equally inhibits all kinases screened. Even though the Gini coefficient does not rely 
on a defined threshold, the coefficient relies on the single concentration tested and 
is thus inherently limited [20, 76].
4.5.3 Selectivity Entropy Value
Following the use of selectivity scores and the Gini coefficient to quantitatively 
describe inhibitor selectivity, Uitdehaag and Zaman [76] introduced the entropy 
value to overcome the limitations of the selectivity score and Gini coefficient score. 
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The entropy value was previously utilized in a diverse range of fields such as ther-
modynamics and chemistry, and it is based on the concept that inhibitor binding to 
multiple kinases will assume a Boltzmann distribution [76]. The entropy equation 
utilized by Uitdehaag and Zaman [76] involves 5 steps based on the association 
constant (Ka, the inverse of the Kd or IC50 values).
A resulting selectivity entropy (Ssel) value of 0 indicates an inhibitor that targets 
one kinase and the higher the Ssel the less specific the compound is for the kinases 
profiled. Uitdehaag and Zaman [76] compared the selectivity entropy value to the 
selectivity score S(3 μM), Ka-Gini (Gini scores based on association constants), 
S(10x) and partition index (not outlined in this review) for data generated using 
the KINOMEscan compared to a radioactive filter binding enzymatic activity assay 
by Millipore. The two methodologies produced highly correlated data using the 
selectivity entropy score, S(3 μM) and Ka-Gini with r
2 correlation values of 0.93, 
0.92 and 0.99, respectively, showing that these three scores are relatively robust. 
Uitdehaag and Zaman [76] also demonstrated that type II and III inhibitors are 
more selective than type I inhibitors consistent with the conclusions drawn by Davis 
et al. [69] using the selectivity score S(3 μM).
4.6 Graphical representation of selectivity
For qualitative rather than quantitative analysis of a compound selectivity, 
different graphical representations have been used to demonstrate the interaction of 
a compound with the whole kinome or kinase panel in the assay. Interaction maps 
and heat maps have been used to represent and compare compound selectivity. 
Interaction maps are based on the phylogenetic tree. In interaction maps, a circle is 
overlaid on a kinase in the kinase phylogenetic tree representing interaction of the 
compound with the kinase and the size of the circle represents potency. That is, the 
larger the circle the higher affinity the compound has for the kinase [68, 70, 76]. 
Graphical representations allow for visual rankings of selectivity and these visual 
observations should align with any quantitative measure chosen [76].
4.7 Cell-based vs. Cell-free selectivity assays
Regardless if binding or enzymatic activity assays are chosen, it is important 
to understand that cell-free in vitro assays may not reflect the activity in cellular 
systems. As such, it is recommended to follow-up cell-free in vitro selectivity 
assays with cell-based selectivity assays in vitro or in vivo animal model  
systems [65, 70, 77].
Cell-based assays are more complex than cell-free based assays and this com-
plexity contributes to the discrepancies between the assays. One source of complex-
ity in cell-based assays is the fact that the phosphorylation state in cells relies on the 
balance between phosphorylation of proteins by kinases and de-phosphorylation 
of proteins by phosphatases and this can lower the required concentration of KIs 
for kinase inhibition. Additionally, our understanding of phosphatase systems 
and their regulators is more limited. Moreover, sensitivities differ when assessing 
different cellular activities such as calcium release, IL-2 secretion or proliferation of 
T-cells [65] as measures for enzymatic reaction and selectivity.
An important difference between cell-based and cell-free selectivity assays 
is that in the cell-based assay the KI must penetrate the cell membrane and the 
cellular compartments in order for the inhibitor to reach its target. Different factors 
determine if a KI reaches its target within a cell. A KI can penetrate a cell either via 
a diffusion concentration gradient or active transport and a KI can also be actively 
pumped out of cells via efflux mechanisms. Size, lipophilic properties, aqueous 
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solubility, plasma membrane partitioning and plasma protein binding, for in vivo 
assays, will impact the ability of a KI to reach its target within a cell. It is important 
to test the KI once the compound reaches steady state within the cell and therefore it 
is routine practice to pre-incubate cells with the KI prior to performing a cell-based 
kinase activity assay [65].
The metabolic activity and ATP concentration in cells will also affect inhibitor 
activity within cells. In order to compare IC50 values to Kd values, it is best practice 
to use ATP concentrations equal to the Michaelis constant for ATP (KM, ATP) for 
the particular kinase in an enzymatic assay based on the Cheng-Prusoff equation: 
IC50 = Ki(1 + [ATP]/KM, ATP), whereby Ki is the dissociation constant. However, ATP 
concentrations are generally higher in cellular systems compared to the KM, ATP and 
differences in ATP concentrations may be a source of discrepancy between cell-
based and cell-free selectivity assays [65, 76].
An additional potential difference between cell-based and cell-free selectivity 
assays is that some cell-free screening panels use truncated forms of the kinases and 
interactions between a kinase and inhibitor may differ in the setting of the full-
length kinase.
The conformational state of the kinase should also be taken into consideration 
when assaying the interaction with a KI as many kinases can adopt different con-
formational states. For example, inhibitors that bind to the inactive state of a kinase 
can stabilize the kinase in this state which may not occur in a cell-free assay with a 
truncated form of the kinase [20].
5. Overcoming toxicity with more selective kinase inhibitors
The first generation of KIs, including imatinib, which was the first KI approved 
by the FDA in 2001 for patients with chronic myeloid leukemia (CML), demon-
strated acceptable toxicity profiles in oncology patients compared with traditional 
chemotherapeutic agents, as well as comparable efficacy even though the first 
generation KIs were not highly selective. However, the acceptable toxicity and 
risk–benefit ratio are higher for oncology patients than for patients with conditions 
that are not severely debilitating or life-threatening such as chronic inflammatory 
disease [78]. Therefore, there is a growing need to overcome lack of selectivity and 
off-target toxicities with newly developed KIs for different indications.
An example of overcoming toxicity by improving selectivity and by lowering 
affinity for off-targets is coming from the JAK family of non-receptor tyrosine 
kinases that has gained great interest as therapeutic targets. The JAKs transduce 
signals from a multitude of cytokines and growth factors via the JAK–STAT (Signal 
Transducers and Activators of Transcription) pathway and are involved in various 
inflammatory and autoimmune diseases [79, 80]. Currently, there are four JAK 
inhibitors approved for clinical use: tofacitinib (for RA, psoriatic arthritis, ulcer-
ative colitis), baricitinib (for RA), ruxolitinib and fedratinib (for myelofibrosis). 
These JAK inhibitors demonstrate that improved selectivity results in more favor-
able safety profile, and also emphasize that the existence of off-target binding does 
not automatically predict unfavorable safety profiles because the off-target activity 
plays a major role. That is, lower activity of these JAK inhibitors on their off-targets 
result in lower toxicity. Since JAK inhibitors block downstream signaling of a 
variety of cytokines relevant for normal physiology, various severe adverse effects 
were often predicted for these inhibitors. However, clinical trials of tofacitinib 
have shown an acceptable safety profile, with infection and cytopenias (due to the 
blockage of myelopoietic growth factor signaling through JAK2) being the major 
adverse events, and without any increased risk of developing malignancies [81]. 
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Likewise, the selective JAK1/JAK2 inhibitor baricitinib, which offers an effective 
treatment for RA, demonstrates little effect on hematology parameters, with 
uncommon neutropenia (<1% patients) and no higher risk of infection [82]. A 
reduction in natural killer (NK) cell numbers was observed in some patients, but 
there was no evident association between the low NK cell count and the incidence 
of infections. Ruxolitinib is another potent JAK1/JAK2 inhibitor demonstrating 
dose-dependent inhibition of the JAK2/STAT signaling and inhibition of cell 
growth that is dependent on JAK2 activation, with a sixfold selectivity for JAK1/
JAK2 over Tyk2 and approximately a 130-fold selectivity for JAK1/JAK2 over JAK3 
[83]. Despite this high selectivity, thrombocytopenia and anemia are side effects 
of ruxolitinib which can be dose- or even treatment-limiting adverse events and 
patients who discontinue ruxolitinib have miserable outcomes, making this situa-
tion an area of significant unmet need [84, 85]. Recently, fedratinib was approved 
by the FDA as a different drug for myelofibrosis overcoming some of the toxicities 
and resistance observed in ruxolitinib-refractory patients [86]. Fedratinib is selec-
tive for JAK2 over other JAKs and the common side effects reported with this drug 
include anemia, gastrointestinal symptoms, and elevations in liver transaminases 
[87]. Fedratinib also has a black box warning for encephalopathy, although this 
occurred only in about 1% of the treated patients [87]. Overall, increasing selectiv-
ity of JAK inhibitors may decrease the side effect burden on the patient but this 
cannot be avoided completely due their mechanism of action on important signal 
transduction pathways.
In an attempt to develop more selective second-generation JAK inhibitors, 
there are more than 20 other JAK inhibitors undergoing clinical trials, with vary-
ing selectivity profiles, for a variety of autoimmune diseases, including psoriasis, 
alopecia areata, ankylosing spondylitis and lupus [87]. Within the JAK family, 
JAK3 inhibitors are emerging as potential targets for the design of more selective 
KIs. JAK3 is a potential target for inflammatory diseases and has a more defined 
function than other JAKs, which participate in multiple cellular processes. JAK3 
associates only with the common γ-chain receptor, and it is expressed selectively 
in lymphoid and myeloid cells. Consequently, selective JAK3 inhibition may be 
beneficial in suppressing inflammatory responses with less off-target effects and 
markedly reduced adverse effects [80]. The main concern that has arisen recently 
with JAK inhibitors from pharmacovigilance (real-world data analysis) is a 
higher risk of thromboembolism [88, 89]. Conflicting data indicates that higher 
thromboembolic risk may be related to the specificity of JAK inhibitor action, 
such that preferentially blocking one signaling pathway upsets the balance 
between pro and anti-thrombotic activities [90]. It could be that thromboembolic 
complications are not a general class effect of JAK inhibitors, but might be related 
to inhibition of a specific JAK, aging and mutations in JAKs and the patient clini-
cal history.
Even though the threshold for acceptable toxicities is higher for oncology 
patients due to the higher risk–benefit ratio that is tolerated, effort continues 
to be invested into producing more selective anti-cancer KI treatments with 
fewer side effects because these drugs fail in clinical trials due to overt toxic-
ity. Promising and selective anti-cancer agents are cyclin-dependent kinases 
(CDKs) inhibitors. CDKs are important players in the regulation of cell division 
and proliferation, and numerous drugs that target CDKs have been developed to 
treat cancers over the past 20 years. The clinical trials with the first CDK inhibi-
tors were discontinued due to severe toxicities. These toxicities were related to 
the low selectivity of the CDK inhibitors, since CDKs such as CK1 and CDK2 
that are essential for maintaining the growth and function of normal cells were 
also inhibited [91]. More recently approved CDK inhibitors for the treatment of 
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patients with breast cancer, including palbociclib, ribociclib, and abemaciclib, 
which exhibit selectivity for CDK4/6 over other CDKs, are associated with a lower 
numbers of life-threatening side effects [92]. These inhibitors do not have cross 
reactivity with other CDKs nor with other kinases in general and therefore have 
an improved safety profile [93]. Other selective CDK inhibitors are currently 
under development [94].
6. Conclusion and future perspectives
Hundreds of diseases including various cancers, Alzheimer’s disease and auto-
immune are associated with kinase mediated phosphorylation of proteins, and 
therefore discovery of selective KIs is still an urgent need. Selectivity is a known 
challenge for the development of KIs as safe therapeutics and as reliable tool com-
pounds to investigate biological activities. Therefore, it is important to investigate 
the selectivity of KIs against kinase panels as well as against other targets such as 
other enzymes, ion channels and receptors. As a consequence, the technologies for 
assessing the selectivity of KIs are constantly evolving and have become increas-
ingly sophisticated. In particular, the development of techniques that measure 
inhibitor profiles in environments that mimic human physiology would provide 
more reliable and human relevant results on the KI selectivity. Optimization of 
KIs, either by structure based drug-design, identifying and targeting allosteric 
sites or enhancing affinity for the on-target kinase, improves selectivity, and in 
general more selective KIs were shown to have more favorable safety profiles. 
The recently approved CDK and JAK inhibitors provide a proof of concept that 
safer and more effective KIs can be developed for both oncology indications and 
non-oncology indications such as chronic inflammatory diseases. Recent progress 
in nanomedicine and targeted therapy offers improvement of drug efficacy, and 
allow for specific delivery of TKIs to the diseased cells using special nanocarriers, 
thereby reducing the incidence of adverse events [95]. Yet, TKI-nanomedicines are 
in the initial stages of development and, although they have great potential, they 
still have a long way ahead of them. Overall, achieving improved target selectivity 
and reduced off-target-mediated toxicity using efficient compound screening and 
profiling technologies, providing targeted therapies and overcoming resistance will 
further pave the way for novel, selective and safe KIs as promising therapeutics in 
oncology and beyond.
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